Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
About this trial
This is an interventional treatment trial for Fallopian Tube Cancer focused on measuring stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cavity cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven stage III or IV ovarian epithelial, tubal, or peritoneal adenocarcinoma Must have had complete clinical response to primary therapy consisting of surgical debulking and platinum based chemotherapy Elevated CA 125 (greater than 35 U/mL) prior to or at surgery (if presurgical CA 125 measurement is not available, patient must have a serum CA 125 of at least 100 U/mL and strong tumor tissue expression) Must have residual disease (visible or palpable) at completion of the staging laparotomy (IIIB and IIIC microscopic disease) PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Karnofsky 60-100% Life expectancy: At least 6 months Hematopoietic: Hemoglobin at least 8.0 g/dL Lymphocyte count at least 300/mm3 Neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal Renal: Creatinine no greater than 1.6 mg/dL PRIOR CONCURRENT THERAPY: Biologic therapy: At least 6 weeks since prior immunotherapy No prior murine monoclonal antibodies for diagnostic or therapeutic purposes Chemotherapy: No more than 1 prior regimen of chemotherapy (change in chemotherapy agents is permitted during primary therapy provided that the change is considered to be part of initial chemotherapy regimen) At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior abdominal, abdominopelvic, or pelvic radiotherapy Surgery: At least 4 weeks since prior surgery No more than 1 interval debulking procedure
Sites / Locations
- Alta Bates Comprehensive Cancer Center
- USC/Norris Comprehensive Cancer Center
- Jonsson Comprehensive Cancer Center, UCLA
- Chao Family Comprehensive Cancer Center
- Wilshire Oncology Medical Center
- Stanford University School of Medicine
- University of Colorado Cancer Center
- Patty Berg Cancer Center
- University of Florida Health Science Center - Jacksonville
- Walt Disney Memorial Cancer Institute
- University of Chicago Cancer Research Center
- Saint Mary's Hospital
- Lutheran General Cancer Care Center
- University of Iowa Hospitals and Clinics
- Alton Ochsner Medical Foundation Hospital
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland
- New England Medical Center Hospital
- Henry Ford Hospital
- University of Minnesota Medical School
- Ellis Fischel Cancer Center
- North Shore University Hospital
- State University of New York - Upstate Medical University
- University of Oklahoma
- Spartanburg Regional Medical Center
- Baptist Regional Cancer Center - Knoxville
- University of Texas Southwestern Medical School
- U.S. Oncology
- Cancer Center, University of Virginia HSC
- Swedish Hospital Tumor Institute
- Tom Baker Cancer Center - Calgary
- Cross Cancer Institute
- British Columbia Cancer Agency - Fraser Valley Cancer Centre
- British Columbia Cancer Agency
- Manitoba Cancer Treatment and Research Foundation
- Saint John Regional Hospital
- Nova Scotia Cancer Centre
- Cancer Care Ontario-Hamilton Regional Cancer Centre
- Cancer Care Ontario-London Regional Cancer Centre
- Credit Valley Hospital
- Ottawa Regional Cancer Center - General Division
- Northeastern Ontario Regional Cancer Centre, Sudbury
- Toronto Sunnybrook Regional Cancer Centre
- Centre Universitaire de Sante de l'Estrie
- Centre Hospitalier de l'Universite de Montreal
- Jewish General Hospital - Montreal
- Centre Hospitalier Universitaire de Quebec, Pavillion de Quebec